Literature DB >> 17135779

Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy?

Oner Sanli1, Omer Acar, Murad Celtik, Tayfun Oktar, Isin Kilicaraslan, Faruk Ozcan, Murat Tunc, Tarik Esen.   

Abstract

INTRODUCTION: We estimate the frequency of prostate cancers detected incidentally in radical cystoprostatectomy specimens and discuss whether the prostate cancer status should be determined in patients undergoing radical cystoprostatectomy.
MATERIALS AND METHODS: A total of 97 radical cystoprostatectomies without evidence of prostate cancer on digital rectal examination were performed for transitional cell carcinomas of the bladder between January 2001 and May 2004. The mean patient age at the time of surgery was 66.9 +/- 9.52 (range 49-75) years.
RESULTS: The overall incidence of prostate cancer detected in radical cystoprostatectomy specimens was 21.6% (21/97 specimens). The mean tumor volume was found to be 0.93 +/- 0.81 ml. The tumor volume was >0.5 ml in 12 cases (57.1%). The surgical margin was negative in all cases, and the disease was organ confined in 20 patients (95.2%). Capsular invasion was evident in 2 patients (9.5%), 1 of whom had lymph-node-positive disease.
CONCLUSIONS: Despite the high prevalence of incidental prostate carcinomas among patients with bladder cancer undergoing cystoprostatectomy, the vast majority of the cancers are organ confined. However, the prostate cancer status should be determined on the basis of digital rectal examination and prostate-specific antigen in patients undergoing radical cystoprostatectomy - especially if prostate-sparing cystectomy is planned.

Entities:  

Mesh:

Year:  2006        PMID: 17135779     DOI: 10.1159/000096333

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries.

Authors:  Yi-Ping Zhu; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Yi-Jun Shen; Yao Zhu; Guo-Hai Shi
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

2.  EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.

Authors:  Elif Bilgin Doğru; Yavuz Dizdar; Ece Akşit; Feyyaz Ural; Öner Şanlı; Vildan Yasasever
Journal:  Tumour Biol       Date:  2014-08-20

Review 3.  Concomitant bladder cancer and prostate cancer: challenges and controversies.

Authors:  Antonio Lopez-Beltran; Liang Cheng; Francesco Montorsi; Maria Scarpelli; Maria R Raspollini; Rodolfo Montironi
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

4.  Incidental prostate cancer in patients undergoing radical cystoprostatectomy for bladder cancer.

Authors:  Mustafa Hiros; Hajrudin Spahović; Mirsad Selimović; Sabina Sadović
Journal:  Bosn J Basic Med Sci       Date:  2008-05       Impact factor: 3.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.